During the last session, Medtronic Plc (NYSE:MDT)’s traded shares were 7.51 million, with the beta value of the company hitting 0.80. At the end of the trading day, the stock’s price was $81.24, reflecting an intraday gain of 0.07% or $0.06. The 52-week high for the MDT share is $96.25, that puts it down -18.48 from that peak though still a striking 6.5% gain since the share price plummeted to a 52-week low of $75.96. The company’s market capitalization is $104.19B, and the average trade volume was 7.83 million shares over the past three months.
Medtronic Plc (MDT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. MDT has a Sell rating from 1 analyst(s) out of 15 analysts who have looked at this stock. 7 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.23.
Medtronic Plc (NYSE:MDT) trade information
Medtronic Plc (MDT) registered a 0.07% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.07% in intraday trading to $81.24, hitting a weekly high. The stock’s 5-day price performance is -5.94%, and it has moved by -3.33% in 30 days. Based on these gigs, the overall price performance for the year is -0.17%.
The consensus price target of analysts on Wall Street is $93, which implies an increase of 12.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $93 and $93 respectively. As a result, MDT is trading at a discount of -14.48% off the target high and -14.48% off the low.
Medtronic Plc (MDT) estimates and forecasts
In the rating firms’ projections, revenue will increase 5.17% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.37B as predicted by 24 analyst(s). Meanwhile, a consensus of 24 analyst(s) estimates revenue growth to 8.74B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.92B and 8.4B respectively. In this case, analysts expect current quarter sales to grow by 5.71% and then jump by 3.98% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 0.37%. While earnings are projected to return 1.24% in 2025, the next five years will return 5.58% per annum.
MDT Dividends
Medtronic Plc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Medtronic Plc is 2.80, with the dividend yield indicating at 3.45 percent, continuing the trend of increasing dividends in recent years.
Medtronic Plc (NYSE:MDT)’s Major holders
The next largest institutional holding, with 111.89 million shares, is of BLACKROCK INC.’s that is approximately 8.6517% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $8.81 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Medtronic Plc (MDT) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund. Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 40.17 shares. This amounts to just over 3.13 percent of the company’s overall shares, with a $3.26 billion market value. The same data shows that the other fund manager holds slightly less at 34.72, or about 2.71% of the stock, which is worth about $2.82 billion.
